City page
Copenhagen biotech and pharma directory
Copenhagen is a practical entry point to Medicon Valley, the Danish-Swedish life-science region across the Øresund. The BioInnovation Institute in Copenhagen supports research-based projects in therapeutics, health tech, and bioindustrials. Novo Nordisk’s corporate headquarters is in nearby Bagsværd, while Copenhagen-based and regional profiles in this directory cover therapeutics, vaccines, neuroscience, diagnostics, and related services. Start with the exact site and evidence on every profile: the wider region is connected, but its laboratories, headquarters, and manufacturing facilities are not interchangeable.
Where does this city read strongest?
Therapeutics (8), Cluster (2), and Diagnostics (2). Most visible records: Adcendo ApS, Fuse Vectors ApS, and Galecto, Inc..
Which standards and public evidence are already visible?
GMP (2) and FDA-Inspected (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Copenhagen.
Local sources
Primary sources for the local ecosystem
These links let you verify this page’s local context with the primary institution.
Medicon Valley Alliance
The cross-border life-science organisation for collaboration between eastern Denmark and southern Sweden.
Open sourceBioInnovation Institute
Copenhagen’s research-based innovation hub, supporting projects in therapeutics, health tech, and bioindustrials.
Open sourceNovo Nordisk corporate headquarters
Novo Nordisk’s official location information for its corporate headquarters in Bagsværd, in the Copenhagen area.
Open sourceBy category
Copenhagen by category
Jump into a category page filtered to this country only.
Full list
Copenhagen biotech and pharma directory
14 city records currently match the active filter.
Current review cycle
Adcendo ApS
CopenhagenDenmarkTherapeutics
Copenhagen clinical-stage antibody-drug conjugate biotech with a first- and best-in-class pipeline led by ADCE-D01, a uPARAP-targeted ADC with FDA Fast Track designation for soft-tissue sarcoma.
- Lead
- Michael PehlChief Executive Officer
- Scale
- Clinical-stage ADC development
Current review cycle
Fuse Vectors ApS
CopenhagenDenmarkBiotech
Copenhagen gene-therapy platform biotech developing a cell-free viral vector manufacturing system for scalable AAV production, with pre-seed backing from HCVC and BII and an active R&D site in Leiden, Netherlands.
- Lead
- Jordan TurnbullCo-Chief Executive Officer and Co-Founder
- Scale
- Platform R&D to early process demonstration
Current review cycle
Galecto, Inc.
CopenhagenDenmarkTherapeutics
Nasdaq-listed clinical-stage biotech (GLTO) with Copenhagen operating headquarters, developing small-molecule galectin-3 and LOXL2 inhibitors for fibrosis, oncology, and inflammation.
- Lead
- Hans SchambyeChief Executive Officer
- Scale
- Clinical-stage small-molecule development
Current review cycle
GLX Analytix ApS
CopenhagenDenmarkDiagnostics
Copenhagen glycomics IVD startup building AI-augmented GlycA and GlycB-class biomarker tests for neurodegenerative and autoimmune disease diagnostics and monitoring.
- Lead
- Brian DellavalleChief Executive Officer and Founder
- Scale
- Diagnostics platform development
Current review cycle
Hoba Therapeutics ApS
CopenhagenDenmarkTherapeutics
Copenhagen clinical-stage neuroscience biotech developing non-opioid chronic neuropathic pain and sensorineural hearing loss therapeutics, with lead candidate HB-086 targeting the peripheral nervous system.
- Lead
- Torsten M. MadsenChief Executive Officer
- Scale
- Early clinical-stage biotech
Current review cycle
Acesion Pharma
CopenhagenDenmarkTherapeutics
Copenhagen biotech company developing novel therapies for atrial fibrillation and other cardiac arrhythmias from a Danish clinical-development base.
- Lead
- Anders Haahr MathiesenChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
2cureX
CopenhagenDenmarkDiagnostics
Copenhagen precision-oncology diagnostics company commercializing functional drug-sensitivity testing to guide personalized cancer treatment decisions.
- Lead
- Ole ThastrupCEO
- Scale
- Diagnostics platform
Current review cycle
IO Biotech
CopenhagenDenmarkTherapeutics
Copenhagen immuno-oncology company developing immune-modulating cancer therapeutics and clinical-stage vaccine-based programs from Denmark.
- Lead
- Mai-Britt ZoccaCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
BioInnovation Institute
CopenhagenDenmarkCluster
Copenhagen life-sciences venture-building and laboratory platform supporting company creation, incubation, translational research, and startup infrastructure across therapeutics, biotech tools, and planetary-health programs.
- Lead
- Jens NielsenCEO
- Scale
- Multi-company venture-building and laboratory platform
Current review cycle
Statens Serum Institut
CopenhagenDenmarkResearch
Copenhagen national public-health institute operating infectious-disease surveillance, reference diagnostics, preparedness functions, and laboratory infrastructure central to Denmark's life-sciences and health-security system.
- Lead
- Henrik UllumPresident and CEO
- Scale
- National-scale public-health and diagnostic infrastructure
Current review cycle
Medicon Valley Alliance
CopenhagenDenmarkCluster
Cross-border Danish-Swedish life-science cluster alliance coordinating membership, project development, and infrastructure collaboration across Medicon Valley.
- Lead
- Anette SteenbergChief Executive Officer
- Scale
- Danish-Swedish cluster coordination hub
Current review cycle
Zealand Pharma
CopenhagenDenmarkTherapeutics
Copenhagen-area peptide therapeutics company focused on obesity, metabolic disease, and specialty indications through discovery and late-stage development.
- Lead
- Adam SteensbergPresident and Chief Executive Officer
- Scale
- Global Biopharma
Current review cycle
Genmab A/S
CopenhagenDenmarkTherapeutics
Copenhagen antibody-therapeutics headquarters running Genmab's platform-engineering, translational science, and late-stage oncology execution from its Valby base.
- Lead
- Jan van de WinkelPresident and Chief Executive Officer
- Scale
- Global Biopharma
Current review cycle
H. Lundbeck A/S
CopenhagenDenmarkTherapeutics
Copenhagen-area neuroscience therapeutics company combining brain-disease R&D, regulated pharmaceutical supply, and global commercial operations.
- Lead
- Charl van ZylPresident and CEO
- Scale
- Global Supply
FAQ
Frequently asked questions
- What is Medicon Valley?
- Medicon Valley is a cross-border life-science region linking eastern Denmark and southern Sweden across the Øresund. Medicon Valley Alliance works on Danish-Swedish collaboration among life-science stakeholders. It is useful regional context, not proof that a company has a laboratory, manufacturing site, or commercial presence in every part of the region.
- What companies are in Copenhagen biotech?
- Use the current directory list below for Copenhagen-based records and open each profile for its documented address and sources. Relevant regional organisations include the BioInnovation Institute in Copenhagen and Novo Nordisk in Bagsværd. Other companies may be based elsewhere in the capital region or southern Sweden, so they should be assessed by their actual operating location rather than a regional label.
- What sectors are strongest in Copenhagen biotech?
- The records on this page span therapeutics, vaccines, neuroscience, diagnostics, and research-based company building. For a procurement or partnership decision, use the individual profile’s specialisation, sources, and documented quality evidence; do not infer manufacturing approval or a modality from the city page alone.
Related briefs
Briefs that mention Copenhagen
European mRNA & Immunotherapy Supply Chain 2026
Where the European mRNA, vaccine, and immunotherapy supply chain actually sits in 2026 - BioNTech, CureVac, IDT Biologika, AGC Biologics, BioSpring, Bachem, plus the Nordic vaccine layer - and how the pieces fit.
Open briefEuropean Viral Vector CDMO Guide 2026: AAV, Adenovirus, Lentivirus
A source-backed guide to publicly stated European viral-vector CDMO capabilities in 2026: AAV, adenovirus, lentivirus, pDNA, and the questions to ask before a manufacturing enquiry.
Open briefNordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 - 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.